Hospital Infantil Universitario Niño Jesus de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2024

  1. Adaptación transcultural y validación de cuestionarios WPAI (Work Productivity and Activity Impairment) para cuidadores de pacientes con enfermedad inflamatoria intestinal pediátrica en España. Estudio multicéntrico

    Archivos argentinos de pediatria, Vol. 122, Núm. 6, pp. e202410329

  2. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

    Biomedicine and Pharmacotherapy, Vol. 173

  3. Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

    Pediatric Drugs, Vol. 26, Núm. 5, pp. 609-617

  4. Erratum: Correction to: Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP (European journal of pediatrics (2024) 183 8 DOI: 10.1007/s00431-024-05575-7)

    European journal of pediatrics

  5. Identification of copy-number variants in patients with overgrowth disorders

    Clinical Genetics, Vol. 106, Núm. 5, pp. 614-624

  6. Impact of pediatric inflammatory bowel disease on caregivers' work productivity: A multicenter study by the SEGHNP

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 79, Núm. 3, pp. 573-582

  7. STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN

    European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3253-3262

  8. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  9. Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP

    European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3417-3430

2023

  1. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  3. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  4. Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity

    European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4633-4645

  5. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research, Vol. 194

2022

  1. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 75, Núm. 6, pp. 717-723

2021

  1. Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study (European Journal of Pediatrics, (2021), 180, 9, (3029-3038), 10.1007/s00431-021-04063-6)

    European Journal of Pediatrics

  2. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 2, pp. 447-457

  3. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study

    European Journal of Pediatrics, Vol. 180, Núm. 9, pp. 3029-3038

  4. Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease

    Pharmaceutics, Vol. 13, Núm. 1, pp. 1-17

2020

  1. Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease

    International Journal of Molecular Sciences, Vol. 21, Núm. 9